High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
about
Acetylcholinesterase inhibitors for schizophreniaAdjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacyEffects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.Predictors of early abstinence in smokers with schizophreniaPharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacologyCholinergic connectivity: it's implications for psychiatric disorders.Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders.Comparison of the effectiveness of Conners' CPT and the CPT-identical pairs at distinguishing between smokers and nonsmokers with schizophrenia.Role of the cholinergic system in the pathology and treatment of schizophrenia.Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatmentsNeuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status.The treatment of cognitive impairment in schizophrenia.Emerging drugs for schizophrenia.Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.Can genetics inform the management of cognitive deficits in schizophrenia?Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.Drug repurposing and emerging adjunctive treatments for schizophrenia.Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants.A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
P2860
Q24203876-744F1AF8-4FDA-4722-B18C-D03C37716893Q28297813-86F84A14-D052-4057-A160-F96B60A04614Q30455599-6F89F803-D79B-4492-8540-7C65F24D32B7Q33679772-6A7A9683-5D85-43C9-BA85-7609B6E2200DQ34274859-38BE05B8-F3AE-4F96-B1C7-0C5C10C5EB14Q34502083-B0BA8549-E019-4AEF-A438-09CF8153E935Q36097637-B1577324-E281-45AD-AF5F-64E3FB6DA39BQ36812599-269181AA-2A24-44DB-A018-E085E4E43521Q36813681-3A2752A9-6B8A-4F5E-8499-67D26556520BQ37067243-C49C2D59-CE27-4E27-8E73-C5787E982F61Q37356496-6751CE96-8D56-4E77-9349-BBD476E39428Q37576675-E12BAECC-AB5A-4568-9BC9-FC2F274117E3Q37693834-032D3DB3-278B-410F-8785-37D67BD674ABQ37813206-031D8245-71AF-489A-B80F-069207700870Q37874626-87FFEAE5-C210-4E4F-A394-10B93E7B23CFQ37954123-70CC138F-3A34-45FE-9E99-13217883BA64Q37983548-7652A2F9-30C1-4EAB-B668-71275446B645Q38171876-E83D93B3-52C3-4A81-A38C-F5A415C2A009Q38417631-95E31B92-C872-477A-8F39-39132CA61888Q43613870-A67BB103-D15C-4076-944B-FD88695C8DBBQ47701023-2671DD29-BB58-4078-A171-D2199A85773DQ54975082-A7EDAFD4-DEDE-474F-B84E-EFF65B45EBE5Q58561523-6D179B42-6B77-4C5C-B6B6-D65D6356A0A2
P2860
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High-dose galantamine augmenta ...... nonsmokers with schizophrenia.
@en
High-dose galantamine augmenta ...... nonsmokers with schizophrenia.
@nl
type
label
High-dose galantamine augmenta ...... nonsmokers with schizophrenia.
@en
High-dose galantamine augmenta ...... nonsmokers with schizophrenia.
@nl
prefLabel
High-dose galantamine augmenta ...... nonsmokers with schizophrenia.
@en
High-dose galantamine augmenta ...... nonsmokers with schizophrenia.
@nl
P2093
P2860
P1476
High-dose galantamine augmenta ...... nonsmokers with schizophrenia.
@en
P2093
A Eden Evins
Erin Murphy
Gladys N Pachas
Melissa A Culhane
Michael A Dyer
Oliver Freudenreich
Thilo Deckersbach
P2860
P356
10.1016/J.SCHRES.2007.12.491
P407
P577
2008-03-05T00:00:00Z